Literature DB >> 3154684

Doxorubicin concentrations in plasma and myocardium and their respective roles in cardiotoxicity.

Q Timour1, P Nony, J Lang, M Lakhal, V Trillet, G Faucon.   

Abstract

Three hours after the intravenous infusion of doxorubicin (3 mg/kg over 15 min) to anesthetized dogs, the drug concentration was found much higher in the myocardium than in the plasma (about 4,000 ng/g, i.e., 50 times higher). After the intravenous infusion of doxorubicin (1.5 mg/kg over 15 min) to conscious dogs, the drug concentration appeared to decline very slowly in the myocardium, since it was close to 200 ng/g at the 7th day, whereas the plasma concentration had fallen to zero, and the drug was still detected in the cardiac tissue 21 days after the administration. As myocardial concentrations of doxorubicin persist long after plasma clearance is complete, the hazards of repeated administration, based on plasma kinetic patterns, must be emphasized.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3154684     DOI: 10.1007/bf02125741

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  13 in total

1.  A clinicopathologic analysis of adriamycin cardiotoxicity.

Authors:  E A Lefrak; J Pitha; S Rosenheim; J A Gottlieb
Journal:  Cancer       Date:  1973-08       Impact factor: 6.860

2.  A simple drill-biopsy technique: evaluation for muscular and myocardial biochemical measurements.

Authors:  K Schwartz; P Rey; M de Mendonca
Journal:  J Mol Cell Cardiol       Date:  1973-06       Impact factor: 5.000

3.  Clinical pharmacology of daunorubicin.

Authors:  R S Benjamin
Journal:  Cancer Treat Rep       Date:  1981

4.  Transport and storage of daunorubicin and doxorubicin in cultured fibroblasts.

Authors:  C Peterson; A Trouet
Journal:  Cancer Res       Date:  1978-12       Impact factor: 12.701

5.  Cellular pharmacokinetics of daunorubicin: uptake by leukaemic cells in vivo and fate.

Authors:  V Trillet; M Lakhal; J Lang; E Perrin-Fayolle; Q Timour Chah; D Fière; G Faucon
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.

Authors:  E Piazza; M G Donelli; M Broggini; C Sessa; N Natale; L Ottolenghi; S Marsoni; A Libretti; C Mangioni; L Morasca
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep

7.  Tissue disposition of doxorubicin in experimental animals.

Authors:  Y T Lee; K K Chan; P A Harris
Journal:  Med Pediatr Oncol       Date:  1982

8.  Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study.

Authors:  D S Chervinsky; J J Wang
Journal:  J Med       Date:  1976

9.  Early anthracycline cardiotoxicity.

Authors:  M R Bristow; P D Thompson; R P Martin; J W Mason; M E Billingham; D C Harrison
Journal:  Am J Med       Date:  1978-11       Impact factor: 4.965

10.  Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia.

Authors:  C Paul; R Baurain; G Gahrton; C Peterson
Journal:  Cancer Lett       Date:  1980-06       Impact factor: 8.679

View more
  4 in total

1.  Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.

Authors:  T K Yeung; J W Hopewell; R H Simmonds; L W Seymour; R Duncan; O Bellini; M Grandi; F Spreafico; J Strohalm; K Ulbrich
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Mitochondrial accumulation of doxorubicin in cardiac and diaphragm muscle following exercise preconditioning.

Authors:  Aaron B Morton; Andres Mor Huertas; J Matthew Hinkley; Noriko Ichinoseki-Sekine; Demetra D Christou; Ashley J Smuder
Journal:  Mitochondrion       Date:  2018-02-21       Impact factor: 4.160

Review 3.  The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity.

Authors:  Kerstin N Timm; Damian J Tyler
Journal:  Cardiovasc Drugs Ther       Date:  2020-04       Impact factor: 3.727

4.  Synergistic Antitumor Interaction of Risedronate Sodium and Standard Anticancer Agents in Canine (D-17) and Human Osteosarcoma (U-2 OS) Cell Lines.

Authors:  Dominik Poradowski; Aleksander Chrószcz; Bożena Obmińska-Mrukowicz
Journal:  Animals (Basel)       Date:  2022-03-29       Impact factor: 2.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.